Aprecia Pharmaceuticals products
Spritam (levetiracetam tablets for oral suspension)
Indication: Adjunctive therapy for partial onset seizures, myoclonic seizures, and primary generalized tonic–clonic seizures in epilepsy
Status: First—and currently only—FDA-approved medication manufactured using 3D-printing (ZipDose technology); rapidly disintegrates with a small sip of liquid and is deliverable via NG- and G-tubes
ZipDose Technology
Description: Proprietary 3D-printing platform that enables oral dosage forms with high dose loads that dissolve quickly (even at large tablet sizes)
Application: Used to formulate Spritam and potentially adaptable for other high-dose, easy-swallow drug delivery solutions
No comments:
Post a Comment